Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB3 | P05106 | 4/20 | 0.49 |
| ▸ | ITGAV | P06756 | 4/20 | 0.49 |
| ▸ | THRB | P10828 | 5/20 | 0.43 |
| ▸ | THRA | P10827 | 4/20 | 0.43 |
| ▸ | PPARG | P37231 | 4/20 | 0.43 |
| ▸ | RXRA | P19793 | 3/20 | 0.43 |
| ▸ | PCNA | P12004 | 6/20 | 0.38 |
| ▸ | LMNA | P02545 | 4/20 | 0.37 |
| ▸ | MEN1 | O00255 | 3/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.37 |
| ▸ | ADORA3 | P0DMS8 | 3/20 | 0.37 |
| ▸ | PDE4D | Q08499 | 3/20 | 0.37 |
| ▸ | HSD17B10 | Q99714 | 3/20 | 0.37 |
| ▸ | TTR | P02766 | 2/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.37 |
| ▸ | HTR1A | P08908 | 2/20 | 0.37 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.37 |
| ▸ | HTR2B | P41595 | 2/20 | 0.37 |
| ▸ | PGR | P06401 | 2/20 | 0.37 |
| ▸ | NR3C1 | P04150 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16167659 | 0.90 | ITGB3 (0.50) | ITGB3ITGAVTHRBTHRAPPARG | |
| SCHEMBL6852167 | 0.89 | ITGB3 (0.60) | ITGB3ITGAVTHRBTHRAPPARG | |
| SCHEMBL6852102 | 0.79 | THRB (0.51) | ITGB3ITGAVTHRBTHRAPPARG | |
| SCHEMBL6857392 | 0.78 | THRB (0.52) | ITGB3ITGAVTHRBTHRAPPARG | |
| SCHEMBL23868270 | 0.76 | MEN1 (0.41) | ITGB3ITGAVMEN1KMT2AALDH1A1 | |
| SCHEMBL6852396 | 0.75 | THRB (0.47) | ITGB3ITGAVTHRBTHRAPPARG | |
| SCHEMBL1525946 | 0.75 | THRB (0.73) | ITGB3ITGAVTHRBTHRAPPARG | |
| SCHEMBL24486433 | 0.73 | ITGB3 (0.57) | ITGB3ITGAVTHRBTHRAPPARG | |
| SCHEMBL19677574 | 0.72 | THRB (0.51) | ITGB3ITGAVTHRBTHRAPPARG | |
| SCHEMBL25377857 | 0.71 | KDM1A (0.56) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9580395-B2 | Compositions of dual thyrointegrin antagonists and use in vascular-associated disorders | VASCULAR VISION PHARMACEUTICAL COMPANY (US) | 2017-02-28 | — | — | US | disclosed |
| US-9580395-B2 | Compositions of dual thyrointegrin antagonists and use in vascular-associated disorders | VASCULAR VISION PHARMACEUTICAL COMPANY (US) | 2017-02-28 | — | — | US | disclosed |
| US-20150031688-A1 | COMPOSITIONS OF DUAL THYROINTEGRIN ANTAGONISTS AND USE IN VASCULAR-ASSOCIATED DISORDERS | NANOPHARMACEUTICALS, LLC | 2015-01-29 | — | — | US | disclosed |
| US-20150031688-A1 | COMPOSITIONS OF DUAL THYROINTEGRIN ANTAGONISTS AND USE IN VASCULAR-ASSOCIATED DISORDERS | NANOPHARMACEUTICALS, LLC | 2015-01-29 | — | — | US | disclosed |
| US-8859539-B2 | Compositions of dual thyrointegrin antagonists and use in vascular-associated disorders | VASCULAR VISION PHARMACEUTICAL COMPANY (US) | 2014-10-14 | — | — | US | disclosed |
| US-8859539-B2 | Compositions of dual thyrointegrin antagonists and use in vascular-associated disorders | VASCULAR VISION PHARMACEUTICAL COMPANY (US) | 2014-10-14 | — | — | US | disclosed |
| US-20110105482-A1 | COMPOSITIONS OF DUAL THYROINTEGRIN ANTAGONISTS AND USE IN VASCULAR-ASSOCIATED DISORDERS | VASCULAR VISION PHARMACEUTICAL COMPANY (US) | 2011-05-05 | — | — | US | disclosed |
| US-20110105482-A1 | COMPOSITIONS OF DUAL THYROINTEGRIN ANTAGONISTS AND USE IN VASCULAR-ASSOCIATED DISORDERS | VASCULAR VISION PHARMACEUTICAL COMPANY (US) | 2011-05-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150031688-A1 | COMPOSITIONS OF DUAL THYROINTEGRIN ANTAGONISTS AND USE IN VASCULAR-ASSOCIATED DISORDERS | TEK, THRA, TSHR | ITGB3 9/4885ITGAV 7/4885THRB 4/4885 |
| US-20110105482-A1 | COMPOSITIONS OF DUAL THYROINTEGRIN ANTAGONISTS AND USE IN VASCULAR-ASSOCIATED DISORDERS | TEK, THRA, TSHR | ITGB3 9/4885ITGAV 7/4885THRB 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.